SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 3rd, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2019, between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Saiid Zarrabian President and Chief Executive Officer DelMar Pharmaceuticals, Inc. Suite 720-999 West Broadway Vancouver, British Columbia, Canada V5Z 1K5 Dear Mr. Zarrabian:Zarrabian • June 3rd, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim”), Dawson James Securities, Inc. (“DJ” and together with Maxim, the “Placement Agents”) and Delmar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), pursuant to which the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of common stock (the “Shares”) of the Company, par value $0.001 per share (“Common Stock”), warrants to purchase Common Stock (the “Warrants” and, collectively with the Shares, the “Securities”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that the Placement Agents would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete th
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.DelMar Pharmaceuticals, Inc. • June 3rd, 2019 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [____] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [__]1 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [ ], 20242 (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
